Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma
Authors:
- Chen LiuCLChen Liu
- He ChengHCHe Cheng
- Kaizhou JinKJKaizhou Jin
- Meng GuoMGMeng Guo
- Yu LuYLYu Lu
- Zhengshi WangZWZhengshi Wang
- Chao YangCYChao Yang
- Jiang LongJLJiang Long
- Quanxing NiQNQuanxing Ni
- Xianjun YuXYXianjun Yu
- Guopei LuoGLGuopei Luo
- 1 July 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 47 (6) , 742-747
Abstract
Objectives: Notable modifications have been made in the American Joint Committee on Cancer (AJCC) Staging eighth edition staging for pancreatic cancer for the consideration of the irreproducible and inapplicable of the AJCC seventh edition staging. However, the new staging classification has not been systemically verified. Methods: A comparison was performed to evaluate the application of the AJCC seventh and eighth staging classifications using the Surveillance, Epidemiology, and End Results registry (18,450 patients) and an institutional series (2040 patients). Results: For the eighth staging classification, patients with tumor diameter of greater than 4 cm (T3N0M0, IIA) had similar prognosis to patients with 1 to 3 positive nodes (T1–3N1M0, IIB). For patients who underwent tumor resection and without lymph node involvement, survival curves of T1 (≤2 cm), T2 (2–4 cm), and T3 (>4 cm) were well separated. Statistical difference in survival analyses was demonstrated in N0 (0 positive node), N1 (1–3 positive nodes), and N2 (≥4 positive nodes) patients underwent tumor resection. The AJCC eighth edition had better stage distribution than the AJCC seventh edition for pancreatic cancer. Conclusions: The eighth edition of AJCC staging is more applicable and accurate than the seventh edition for pancreatic adenocarcinoma.Keywords
This publication has 12 references indexed in Scilit:
- Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 2017
- Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas SocietyPancreas, 2017
- Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic AdenocarcinomaAnnals of Surgery, 2017
- Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert CentersJournal of Clinical Oncology, 2016
- Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2–≤4, pT3: >4 cm) is More Valid and Clinically RelevantAnnals of Surgical Oncology, 2016
- Cancer statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM StagingAnnals of Surgical Oncology, 2015
- Pancreatic AdenocarcinomaAnnals of Surgery, 2015
- Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with ChemotherapyAnnals of Surgical Oncology, 2014
- Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, ChinaCancer Letters, 2014